Events

Recall of Extracorporeal Circulatory Circulation (ECC)

According to L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), this recall involved a device in France that was produced by MEDTRONIC.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Date
    2008-05-21
  • Event Country
    France
  • Event Source
    ANSM
  • Event Source URL
    https://ansm.sante.fr/S-informer/Informations-de-securite-Retraits-de-lots-et-de-produits/rappel-et-information-concernant-des-dispositifs-de-circulation-extra-corporelle-de-la-societe-medtronic
  • Notes / Alerts
    French data is current through early September 2018. All of the data comes from L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and France.
  • Extra notes in the data
  • Action
    Some of the Medtronic Extracorporeal Circulatory Circulation (ECC) devices were manufactured with heparin lots contaminated with persulfated chondroitin. Medtronic, in agreement with Afssaps and following the risk analysis it conducted on these products, decided to. recall CEC devices with Carmeda® surface treatment. The attached letter (21/05/2008) (31 KB) has been sent to the users concerned. make facilities available for Trillium® surface treatment CECs until uncontaminated alternatives are available. The enclosed information letter (21/05/2008) (34 KB) has been distributed to users. This action was considered acceptable to the extent that no adverse effects have been reported to date, the heparin used was poorly contaminated and the exposure when using medical devices is less than direct injection heparin. Medtronic informed the customers concerned of the actions carried out on 16 May 2008. The competent European authorities have been informed of this measure by the manufacturer. This information is addressed to the directors of health establishments and local correspondents of materiovigilance for diffusion to the concerned services.

Device

Extracorporeal Circulatory Circulation (ECC)
  • Model / Serial
  • Product Description
    medical_device
  • Manufacturer
    MEDTRONIC

Manufacturer

MEDTRONIC
  • Manufacturer Parent Company (2017)
    Medtronic plc
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    LAANSM